MicroRNA expression profiles for the NCI-60 cancer cell panel

Advances in the understanding of cancer cell biology and response to drug treatment have benefited from new molecular technologies and methods for integrating information from multiple sources. The NCI-60, a panel of 60 diverse human cancer cell lines, has been used by the National Cancer Institute to screen >100,000 chemical compounds and natural product extracts for anticancer activity. The NCI-60 has also been profiled for mRNA and protein expression, mutational status, chromosomal aberrations, and DNA copy number, generating an unparalleled public resource for integrated chemogenomic studies. Recently, microRNAs have been shown to target particular sets of mRNAs, thereby preventing translation or accelerating mRNA turnover. To complement the existing NCI-60 data sets, we have measured expression levels of microRNAs in the NCI-60 and incorporated the resulting data into the CellMiner program package for integrative analysis. Cell line groupings based on microRNA expression were generally consistent with tissue type and with cell line clustering based on mRNA expression. However, mRNA expression seemed to be somewhat more informative for discriminating among tissue types than was microRNA expression. In addition, we found that there does not seem to be a significant correlation between microRNA expression patterns and those of known target transcripts. Comparison of microRNA expression patterns and compound potency patterns showed significant correlations, suggesting that microRNAs may play a role in chemoresistance. Combined with gene expression and other biological data using multivariate analysis, microRNA expression profiles may provide a critical link for understanding mechanisms involved in chemosensitivity and chemoresistance. [Mol Cancer Ther 2007;6(5):1483–91]

[1]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[2]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[3]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[4]  J N Weinstein,et al.  A protein expression database for the molecular pharmacology of cancer , 1997, Electrophoresis.

[5]  C. Croce,et al.  MicroRNA-cancer connection: the beginning of a new tale. , 2006, Cancer research.

[6]  J. Weinstein,et al.  Karyotypic "state" as a potential determinant for anticancer drug discovery. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[8]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Barbacioru,et al.  Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1 , 2005, The Pharmacogenomics Journal.

[10]  C. Croce,et al.  MicroRNAs and chromosomal abnormalities in cancer cells , 2006, Oncogene.

[11]  Tushar Patel,et al.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.

[12]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[14]  J. Weinstein,et al.  Transcriptomic analysis of the NCI-60 cancer cell lines. , 2003, Comptes rendus biologies.

[15]  Gabriel S. Eichler,et al.  Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells , 2006, Molecular Cancer Therapeutics.

[16]  M. Jovanović,et al.  miRNAs and apoptosis: RNAs to die for , 2006, Oncogene.

[17]  John N Weinstein,et al.  Integromic analysis of the NCI-60 cancer cell lines. , 2004, Breast disease.

[18]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[19]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  David J. Groggel,et al.  Practical Nonparametric Statistics , 2000, Technometrics.

[21]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[22]  John N. Weinstein,et al.  Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines , 2006, Molecular Cancer Therapeutics.

[23]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Weinstein.  'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. , 2002, Current opinion in pharmacology.

[25]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[26]  Ying Huang,et al.  Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. , 2005, Cancer research.

[27]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  William C Reinhold,et al.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. , 2003, Cancer research.

[29]  G. Hutvagner,et al.  Principles and effects of microRNA-mediated post-transcriptional gene regulation , 2006, Oncogene.

[30]  Jason H. Moore,et al.  Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. , 2007, Cancer research.

[31]  C. Croce,et al.  An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Weinstein,et al.  Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.

[33]  Ruili Huang,et al.  Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small‐molecule screening and structural databases , 2005, Proteins.

[34]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[35]  Ying Huang,et al.  Prediction of Anticancer Drug Potency from Expression of Genes Involved in Growth Factor Signaling , 2006, Pharmaceutical Research.

[36]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[37]  Sergio Contrino,et al.  The ArrayExpress gene expression database: a software engineering and implementation perspective , 2005, Bioinform..

[38]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[39]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[40]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[41]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[42]  Anders Wallqvist,et al.  Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data , 2003, Bioinform..

[43]  A. Hatzigeorgiou,et al.  TarBase: A comprehensive database of experimentally supported animal microRNA targets. , 2005, RNA.

[44]  Ruili Huang,et al.  Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells , 2005, Molecular Cancer Therapeutics.

[45]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[46]  Ali S. Hadi,et al.  Finding Groups in Data: An Introduction to Chster Analysis , 1991 .

[47]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.